title: 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study.
abstract: OBJECTIVE
  This study was performed to quantify the risk of renal disease in patients using aminosalicylates (5-ASA).
  
  
  METHODS
  Data from the United Kingdom General Practice Research Database were used to estimate the incidence of renal disease in adult patients with inflammatory bowel disease (IBD) or prescription for 5-ASA and in patients without IBD. In a nested case-control analysis, each case of renal disease was matched to 5 controls.
  
  
  RESULTS
  Among the 19,025 5-ASA users with IBD, 130 patients developed renal disease (incidence rate of 0.17 cases per 100 patients per year). The incidence among patients with IBD but without 5-ASA use was 0.25 and among patients without IBD was 0.08. In the case-control analysis, the crude odds ratio (OR) for renal disease in current 5-ASA users was 1.60 (95% confidence interval [95% CI]: 1.14-2.26); the adjusted OR was 0.86 (95% CI: 0.53-1.41). For recent users, the crude OR was 4.18 (95% CI: 2.59-6.76) and adjusted OR 2.48 (95% CI: 1.33-4.61); for past users (last prescription more than 12 months before), 1.71 (95% CI: 1.09-2.70) and 0.99 (95% CI: 0.55-1.76), respectively. Although the numbers were small, mesalazine and sulfasalazine users had comparable risks (crude OR for current and recent users of OR 2.08 [95% CI: 1.44-3.01] and 1.84 [95% CI: 1.20-2.82], respectively). In only a few records was renal disease attributed to interstitial nephritis or 5-ASA use.
  
  
  CONCLUSIONS
  Users of 5-ASA have an increased risk of renal disease that may be partly attributable to the underlying disease. Although renal disease is a recognized adverse effect of 5-ASA, the incidence appears to be low and does not appear to be related to either the dose or type of 5-ASA used.
authors.affiliation: Department of Pharmacoepidemiology and Pharmacotherapy, University of Utrecht, Utrecht, Germany.
authors.forename: Tjeerd P
authors.initials: TP
authors.lastname: Van Staa
authors.forename: Simon
authors.initials: S
authors.lastname: Travis
authors.forename: Hubert G M
authors.initials: HG
authors.lastname: Leufkens
authors.forename: Richard F
authors.initials: RF
authors.lastname: Logan
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D016022:Case-Control Studies; D015331:Cohort Studies; D005260:Female; D006801:Humans; D015994:Incidence; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000453:epidemiology*; D008297:Male; D019804:Mesalamine / Q000009:adverse effects*; D008875:Middle Aged; D009395:Nephritis, Interstitial / Q000139:chemically induced / Q000453:epidemiology*; D012307:Risk Factors; D006113:United Kingdom / Q000453:epidemiology
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D019804:Mesalamine